8-K filing — Valion Bio, Inc. (VBIO)
Filed: 2026-10-27 AccNo: 0001437749-26-033552 Size: 214 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Valion Bio Highlights Previously Announced Completion Of Formulation Work On Needle-Free Oral Version Of Acute Radiation Syndrome Drug Entolimod
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Valion Bio Announces Review Of Strategic Options For Contract Manufacturing Unit Velocity Bioworks, Including Possible Sale
Valion Bio's Velocity Biowork Subsidiary Completes Initial Feasibility Evaluation Of LarmorBio's BioScan-NMR Platform
Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company") and LarmorBio, Inc. ("LarmorBio") today announced that Velocity Bioworks, Valion's wholly owned biologics contract development and
Valion Bio Announces Velocity Bioworks' Capabilities To Support Biotechnology Firm Mulling U.S.-Based Production For Biologics Programs
Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation,